Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
Mais filtros











Base de dados
Intervalo de ano de publicação
1.
Drug Metab Dispos ; 41(4): 774-84, 2013 Apr.
Artigo em Inglês | MEDLINE | ID: mdl-23318685

RESUMO

Peginesatide, a polyethylene glycol (PEG)ylated peptide-based erythropoiesis-stimulating agent, stimulates the erythropoietin receptor dimer that governs erythropoiesis. Studies were designed to determine the erythropoietic response, pharmacokinetics (PK), tissue distribution, metabolism, and excretion of peginesatide in nonhuman primates following a single i.v. dose. The PK profile of peginesatide (0.1-5 mg/kg) is characterized by low, dose-dependent plasma clearance; small volume of distribution; and long half-life. The peginesatide PK profile following a single i.v. dose is consistent with the sustained erythropoiesis. Biodistribution quantitative whole-body autoradiography demonstrated high peginesatide levels in bone marrow (i.e., primary hematopoietic site) as well as other known hematopoietic sites persisting through at least 3 weeks at 2.1 mg/kg. Microautoradiography analysis at 48 hours postdose revealed uniform and high distribution of radioactivity in the bone marrow and splenic red pulp with less extensive distribution in the renal cortex (glomeruli, associated ducts, interstitial cells). Radioactivity in the kidney was most prominent in the outer medullary and papillary interstitium. At 2 weeks after dosing, cumulative radioactivity recovery in the urine and feces was 60 and 7% of the administered dose, respectively, with most of the radioactivity associated with the parent molecule. In conclusion, the PK characteristics are consistent with a PEGylated peptide of a 45-kDa molecular mass, specifically low volume of distribution and long half-life. Drug was localized principally to hematopoietic sites, and nonspecific tissue retention was not observed. The nonhuman primate data indicate that peginesatide is metabolically stable and primarily excreted in the urine.


Assuntos
Hematínicos/administração & dosagem , Hematínicos/farmacocinética , Peptídeos/administração & dosagem , Peptídeos/farmacocinética , Administração Intravenosa , Animais , Disponibilidade Biológica , Medula Óssea/diagnóstico por imagem , Medula Óssea/metabolismo , Relação Dose-Resposta a Droga , Eritropoese/efeitos dos fármacos , Hematínicos/metabolismo , Hematínicos/farmacologia , Rim/diagnóstico por imagem , Rim/metabolismo , Macaca fascicularis , Masculino , Peptídeos/metabolismo , Peptídeos/farmacologia , Cintilografia , Baço/diagnóstico por imagem , Baço/metabolismo
2.
Vet Ther ; 11(4): E1-10, 2010.
Artigo em Inglês | MEDLINE | ID: mdl-21308663

RESUMO

To investigate the cutaneous distribution, localization, and persistence of imidacloprid in dogs, Advantage Topical Solution labeled with carbon 14 ((14)C) was topically applied as a single treatment at label rates and application pattern based on body weight to two adult beagles. One dog (8.5 kg) received 1.0 mL of the test solution at a single spot in the interscapular area (14 mg active ingredient/kg body weight); the second dog (12.3 kg) was treated with 2.5 mL of the test solution at four sites, each site receiving approximately 0.625 mL, along the dorsal thoracic and lumbar spine area (21 mg active ingredient/kg body weight). Samples of hair, skin surface residue, and skin taken from the application sites and/or distal body regions of the dogs at four intervals between 7 and 56 days after treatment demonstrated the migration of (14)C radioactivity from the application sites to distal areas of the canine haircoat and skin. The (14)C radioactivity concentrations in the skin biopsy and stratum corneum samples diminished steadily over 56 days after treatment. Microautoradiography of the skin showed focal concentrations of radioactivity in the superficial epidermis, hair follicles, and sebaceous glands. The presence of imidacloprid-derived radioactivity within hair follicles and sebaceous glands and on the skin surface is in good agreement with the reported efficacy of imidacloprid against fleas on dogs and cats for up to 1 month despite posttreatment bathing, shampooing, and/or swimming.


Assuntos
Cães/metabolismo , Imidazóis/farmacocinética , Inseticidas/farmacocinética , Nitrocompostos/farmacocinética , Pele/metabolismo , Administração Tópica , Animais , Feminino , Imidazóis/administração & dosagem , Inseticidas/administração & dosagem , Masculino , Neonicotinoides , Nitrocompostos/administração & dosagem , Pele/química , Distribuição Tecidual
3.
Bioorg Med Chem Lett ; 13(3): 533-8, 2003 Feb 10.
Artigo em Inglês | MEDLINE | ID: mdl-12565966

RESUMO

Based on the realization that N-alkyl 5-arylidene-2-thioxo-1,3-thiazolidin-4-ones are tumor necrosis factor-alpha antagonists, we discovered two additional classes of antagonists: 3-thioxo-2,3-dihydro-1H-imidazo[1,5-a]indol-1-ones (via rational design) and 5-arylidene-2-thioxodihydropyrimidine-4,6(1H,5H)-diones (via computer-guided screening). Chemical modification of the lead structures showed that the structure-activity relationship profiles for both of these series were dependent on the electronic properties of the molecules. Subsequent studies showed that they were light-dependent inhibitors.


Assuntos
Indóis/síntese química , Indóis/farmacologia , Pirimidinas/síntese química , Pirimidinas/farmacologia , Fator de Necrose Tumoral alfa/antagonistas & inibidores , Animais , Antígenos CD40/metabolismo , Células CHO , Cricetinae , Desenho de Fármacos , Eletroquímica , Indicadores e Reagentes , Luz , Relação Estrutura-Atividade , Fator de Necrose Tumoral alfa/efeitos da radiação
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA